The power of autogenous vaccines (autovaccines)

Vaccines are undoubtfully the most important pharmaceutical tool to prevent animal disease and improve health & welfare in livestock animals.

Anyway, there isn‘t a registered vaccine for every disease and animal species available or even established. Sometimes registered vaccines do not adequately meet the pathogen spectra that is present on a farm or newly emerging types of pathogens might occur and registered vaccines can become ineffective. In some cases, such as in minor species and/or minor indications, prevention cannot be sought in registered vaccines because these are usually not available.

Autogenous vaccines are specifically produced for a farm or its epidemiological unit with farm-specific strains of bacteria and/or viruses. The need for autogenous vaccines emerged from the gaps left by registered vaccines. Autogenous vaccines can fill in these gaps. They enable veterinarians to respond quickly and effectively to specific infection scenarios and therefore play a crucial role in maintaining animal health.

Currently, societal pressure on the use of antimicrobials is increased, stressing the need of autogenous vaccines because of their contribution to reduction of antimicrobial resistance. Furthermore, focusing on prevention instead of therapy contributes to animal welfare, another stressed societal theme.

At Dopharma we offer services and support to our Dophavacc customers during the process of composing a vaccine to a follow-up on efficacy and safety of our vaccines.

Contact us to learn more about herd-specific disease-management and Dophavacc autogenous vaccines.

What is Dophavacc®?

Dophavacc is the brand name of Dopharma‘s autogenous vaccines produced by Ripac-Labor.

Ripac-Labor, located in Potsdam Science Park Golm in Germany, has over 2 decades of experience in the field of veterinary diagnostics and production of autogenous vaccines.

The acquisition of Ripac-Labor by Dopharma BV in 2021 led to the establishment of the Dophavacc brand. Large investments are made in R&D and in the diagnostic and production sites of Ripac-Labor to comply with future (GMP) regulatory requirements for the production of autogenous vaccines.

Ripac-Labor is authorized to produce autogenous vaccines by regular inspections of the German authorities. In addition, Ripac-Labor is an active member of the EMAV to guarantee the quality of autogenous vaccines in GMP legislation as well.

Dophavacc autogeneous vaccines from Ripac Labor

The production of Dophavacc®

A thorough and correct diagnostic investigation of the clinical symptoms is the start of every production of autogenous vaccines. It is essential to take the right diagnostic samples from clinical representative animals in order to culture the causative pathogens at Ripac-Labor. After sampling care should be given to a fast and traceable shipment of diagnostic material under the right conditions.
After culturing and identification of the relevant pathogens, Ripac-Labor diagnostics team stores them in its strain collection for a later vaccine production.

The bridge between diagnostics and vaccine production is the master strain collection. It contains all of the clearly identified and characterised preserved isolates. With the information of the strain collection, the infection and vaccination history of each individual herd can be traced. Simultaneously, epidemiological trends in the occurrence of infections become apparent.

The complete process of diagnostics and vaccine production is complex and many steps are necessary to ensure quality and compliance.

For consultation on diagnostics and/or the composition of the vaccine, please feel free to contact the local Dopharma technical support team.

Together, we can build a healthier future for our animals and farmers.

Cattle icon


Sheep & Goats